In vitro and in vivo activity of cyclopeptide Dmt-c[D-Lys-Phe-Asp] NH2, a mu opioid receptor agonist biased toward beta-arrestin

摘要

Morphine and related drugs, which are the most effective analgesics for the relief of severe pain, act through activating opioid receptors. The endogenous ligands of these receptors are opioid peptides which cannot be used as antinociceptive agents due to their low bioactivity and stability in biological fluids. The major goal of opioid research is to understand the mechanism of action of opioid receptor agonists in order to improve therapeutic utility of opioids. Analgesic effects of morphine are mediated mostly through activation of the mu opioid receptor. However, in the search for safer and more effective drug candidates, analogs with mixed opioid receptor profile gained a lot of interest. Recently, the concept of biased agonists able to differentially activate GPCR downstream pathways, became a new approach in the design of novel drug candidates. It is hypothesized that compounds promoting G-protein signaling may produce analgesia while beta-arrestin recruitment may be responsible for opioid side effects. In this report we showed that replacement of the tyrosine residue in the muselective ligand Tyr-c[D-Lys-Phe-Asp] NH2 with 2', 6'-dimethyltyrosine (Dmt) produced a cyclopeptide Dmt-c[D-Lys- Phe-Asp] NH2 with mu/delta opioid receptor agonist profile. This analog showed improved antinociception in the hot-plate test, probably due to the simultaneous activation of mu and delta receptors but also significantly inhibited the gastrointestinal transit. Using the bioluminescence resonance energy transfer (BRET) assay it was shown that this analog was a mu receptor agonist biased toward beta-arrestin. beta-Arrestin-dependent signaling is most likely responsible for the observed inhibition of gastrointestinal motility exerted by the novel cyclopeptide.